Physician profile
Hanan Hussein
NPI 1871786566
$10,666.22
in general payments reported to CMS, 2019-2025
61 companies · $2,047 in 2025
The $2,047 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $643 · 2021: $1,875 · 2022: $1,054 · 2023: $2,213 · 2024: $2,551 · 2025: $2,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,811.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,472.51 | 2021-2025 | |
| Novo Nordisk INC | $1,006.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $988.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $825.85 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $759.23 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merz North America, INC. | $593.84 | 2021 | |
| Amgen INC. | $524.38 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $481.27 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.07 | 2024-2025 | Caplyta |
| Abbott Laboratories | $293.87 | 2022-2025 | Freestyle Libre 3 |
| Corium, LLC | $214.07 | 2023-2025 | Azstarys |
| Allergan, INC. | $200.06 | 2020-2022 | |
| Astellas Pharma US INC | $180.18 | 2023-2025 | Veozah, Myrbetriq |
| Bausch Health US, LLC | $175.19 | 2021-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $159.44 | 2022-2025 | Vyepti, Rexulti |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanan Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.